These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 9103514)
21. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. Edeki TI; He H; Wood AJ JAMA; 1995 Nov 22-29; 274(20):1611-3. PubMed ID: 7474246 [TBL] [Abstract][Full Text] [Related]
22. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329 [TBL] [Abstract][Full Text] [Related]
23. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106 [TBL] [Abstract][Full Text] [Related]
24. CYP2D6 polymorphism is not crucial for the disposition of selegiline. Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797 [TBL] [Abstract][Full Text] [Related]
26. A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. Yue QY; Svensson JO; Sjöqvist F; Säwe J Br J Clin Pharmacol; 1991 Jun; 31(6):643-7. PubMed ID: 1867958 [TBL] [Abstract][Full Text] [Related]
27. Biotransformation, Using Recombinant CYP450-Expressing Baker's Yeast Cells, Identifies a Novel CYP2D6.10 Williams IS; Gatchie L; Bharate SB; Chaudhuri B ACS Omega; 2018 Aug; 3(8):8903-8912. PubMed ID: 31459022 [TBL] [Abstract][Full Text] [Related]
28. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371 [TBL] [Abstract][Full Text] [Related]
30. Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. Kim I; Barnes AJ; Oyler JM; Schepers R; Joseph RE; Cone EJ; Lafko D; Moolchan ET; Huestis MA Clin Chem; 2002 Sep; 48(9):1486-96. PubMed ID: 12194925 [TBL] [Abstract][Full Text] [Related]
31. Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. Gelston EA; Coller JK; Lopatko OV; James HM; Schmidt H; White JM; Somogyi AA Br J Clin Pharmacol; 2012 May; 73(5):786-94. PubMed ID: 22092298 [TBL] [Abstract][Full Text] [Related]
32. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. Park JY; Kim KA; Park PW; Park CW; Shin JG Clin Pharmacol Ther; 2003 Oct; 74(4):334-40. PubMed ID: 14534520 [TBL] [Abstract][Full Text] [Related]
33. Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease. Molanaei H; Carrero JJ; Heimbürger O; Nordfors L; Lindholm B; Stenvinkel P; Odar-Cederlöf I; Bertilsson L Eur J Clin Pharmacol; 2010 Mar; 66(3):269-73. PubMed ID: 19940985 [TBL] [Abstract][Full Text] [Related]
34. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Willmann S; Edginton AN; Coboeken K; Ahr G; Lippert J Clin Pharmacol Ther; 2009 Dec; 86(6):634-43. PubMed ID: 19710640 [TBL] [Abstract][Full Text] [Related]
35. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Chalon SA; Desager JP; Desante KA; Frye RF; Witcher J; Long AJ; Sauer JM; Golnez JL; Smith BP; Thomasson HR; Horsmans Y Clin Pharmacol Ther; 2003 Mar; 73(3):178-91. PubMed ID: 12621383 [TBL] [Abstract][Full Text] [Related]
36. Influence of debrisoquin phenotype on the inducibility of propranolol metabolism. Shaheen O; Biollaz J; Koshakji RP; Wilkinson GR; Wood AJ Clin Pharmacol Ther; 1989 Apr; 45(4):439-43. PubMed ID: 2702801 [TBL] [Abstract][Full Text] [Related]
37. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Susce MT; Murray-Carmichael E; de Leon J Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1356-8. PubMed ID: 16631290 [TBL] [Abstract][Full Text] [Related]
38. Actions and metabolism of codeine (methylmorphine) administration by continuous intravenous infusion to humans. Nomof N; Elliott HW; Parker KD Clin Toxicol; 1977 Dec; 11(5):517-29. PubMed ID: 608317 [TBL] [Abstract][Full Text] [Related]
39. Quantification of the O- and N-demethylated and the glucuronidated metabolites of codeine relative to the debrisoquine metabolic ratio in urine in ultrarapid, rapid, and poor debrisoquine hydroxylators. Yue QY; Alm C; Svensson JO; Säwe J Ther Drug Monit; 1997 Oct; 19(5):539-42. PubMed ID: 9357098 [TBL] [Abstract][Full Text] [Related]
40. Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone. Kim KA; Park PW; Liu KH; Kim KB; Lee HJ; Shin JG; Park JY J Clin Pharmacol; 2008 Jan; 48(1):66-72. PubMed ID: 18094221 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]